Last year, we reported on Sandoz’ victory in its appeal regarding the validity of two of Bayer’s Australian Xarelto® (rivaroxaban) patents…
The End of the Road: High Court refuses Bayer’s Rivaroxaban Patents Special Leave Application
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast® for the week ending 7 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 March 2025 are set out below:
Opposition Succeeds as Claimed Polymorph No Different to Prior Art, Based On ‘Gold Standard’ Comparison
In October 2024, Delegate C. Mitchell of the Australian Patent Office upheld a decision to reject AFT Pharmaceuticals’ (AFT) drug combination patent applications – AU2022201576 (’576) and its divisional child
Pearce IP BioBlast® for the week ending 28 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 February 2025 are set out below:
The Right Dose: Opposition to Janssen’s Dosing Regimen Patent Amendments Denied
In a split 3:2 decision, Gordon A-CJ, Edelman and Steward JJ of the High Court (the Majority) has dismissed the Commonwealth’s appeal in which the Commonwealth sought to overturn the decision of Justice Nicholas
Pearce IP BioBlast® for the week ending 21 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 February 2025 are set out below:
Pearce IP BioBlast® for the week ending 14 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
Cold Comfort: AFT’s Cold and Flu Combination Medicine Patent Applications Found Obvious
In October 2024, Delegate C. Mitchell of the Australian Patent Office upheld a decision to reject AFT Pharmaceuticals’ (AFT) drug combination patent applications – AU2022201576 (’576) and its divisional child
Pearce IP BioBlast® for the week ending 7 February 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 February 2025 are set out below:
High Court Ends 14-Year Clopidogrel Dispute: Commonwealth’s Claim for Damages Dismissed in 3:2 Split Decision
In a split 3:2 decision, Gordon A-CJ, Edelman and Steward JJ of the High Court (the Majority) has dismissed the Commonwealth’s appeal in which the Commonwealth sought to overturn the decision of Justice Nicholas
Out to Pasture: Delayed Injunction Application Fails in Veterinary Patent Battle
Justice Jackman of the Federal Court has refused to grant Virbac (Australia) Pty Ltd (Virbac) an interlocutory injunction to restrain Abbey Laboratories Pty Ltd (Abbey) from launching a generic version of Virbac’s Cydectic Platinum, used to treat and control parasites in beef and dairy cattle. Justice Jackman’s decision confirms the importance of not delaying when seeking injunctive relief, while also highlighting the relative difficulties faced by each party to quantify its potential losses.
Permit Required: Full Court Denies Access to Costs Appeal in Carpark Patent Saga
The Full Federal Court has refused leave to appeal from costs orders made following the successful appeal in the long-running dispute between Vehicle Monitoring Systems (VMS), and SARB Management Group (SARB) and the City of Melbourne (CoM), over parking sensor technology.
Pearce IP BioBlast® for the week ending 31 January 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 January 2025 are set out below:
Pearce IP BioBlast® for the week ending 24 January 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22 December 2024 to 17 January 2025 are set out below:
Pearce IP BioBlast® for the period 22 December 2024 to 17 January 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22 December 2024 to 17 January 2025 are set out below:
A Matter of Taste: IPONZ Decision Serves Up Important Reminders on Patent Practice
In October 2024, the Intellectual Property Office of New Zealand (IPONZ) issued a decision concerning a patent application by Suntory Holdings Limited (Suntory) relating to the enhancement of sweetness in beverages using specific combinations of high-intensity sweeteners and sodium, while maintaining